Related by context. All words. (Click for frequent words.) 61 recurrent glioblastoma multiforme GBM 60 indolent NHL 60 lupus nephritis 60 recurrent glioblastoma 60 cell lymphoma CTCL 59 medullary thyroid cancer 59 superficial bladder cancer 59 recurrent glioblastoma multiforme 59 TTF Therapy 59 heavily pretreated 59 myelofibrosis 59 acute myelogenous leukemia AML 59 leukemia AML 59 myelodysplastic syndrome MDS 58 ganetespib 58 ZYBRESTAT 58 hematological malignancy 58 forodesine 57 pediatric malignancies 57 relapsed multiple myeloma 57 grade gliomas 57 neuroendocrine tumors 57 carcinoid tumors 57 Acute myeloid leukemia AML 57 smoldering myeloma 57 Hepatocellular Carcinoma HCC 57 bronchogenic carcinoma 57 differentiated thyroid 57 radiation sensitizer 57 post herpetic neuralgia 57 alvespimycin 57 metastatic lung cancer 57 refractory NSCLC 57 metastatic malignant melanoma 57 phase IIb clinical 56 ponatinib 56 Omacetaxine 56 metastatic melanoma 56 cutaneous T 56 invasive aspergillosis 56 malignant pleural mesothelioma 56 neuroendocrine cancers 56 anaplastic 56 Glioblastoma Multiforme 56 idiopathic pulmonary fibrosis IPF 56 pancreatic NET 56 Follicular lymphoma 56 Phase III HEAT 56 fosbretabulin 56 Idiopathic Pulmonary Fibrosis 56 colorectal liver metastases 56 BR.# 56 SJIA 55 Pseudomonas aeruginosa infections 55 pancreatic adenocarcinoma 55 hepatocellular cancer 55 acute leukemias 55 recurrent ovarian cancer 55 acute promyelocytic leukemia APL 55 gastrointestinal stromal tumor GIST 55 Ceflatonin 55 Glioblastoma multiforme GBM 55 allogeneic HSCT 55 Cimzia TM 55 relapsed SCLC 55 lymphoma CTCL 55 vemurafenib 55 Ophena TM 55 hypoparathyroidism 55 candidemia 55 heterozygous FH 55 Acute Myelogenous Leukemia AML 55 smoldering multiple myeloma 55 hypercalcemia 55 cutaneous T cell 55 therapeutic regimens 55 thymoma 55 HER2 overexpression 55 Fludara ® 55 romidepsin 55 chronic lymphocytic leukemia CLL 55 vandetanib 55 Acute myeloid leukemia 55 recurrent NSCLC 55 rALLy 55 pulmonary hypertension PH 55 hormone deprivation 55 metastatic renal cell carcinoma 55 Glioblastoma Multiforme GBM 55 seminoma 55 Alemtuzumab 54 ruxolitinib 54 ADHF 54 remission induction 54 sapacitabine 54 Glioblastoma 54 oral ridaforolimus 54 systemic ALCL 54 pheochromocytoma 54 CYT# potent vascular disrupting 54 Glioblastoma multiforme 54 Gleevec resistant 54 relapsing remitting MS RRMS 54 malignant neoplasm 54 invasive fungal infections 54 Hypotension 54 gastrointestinal stromal tumors GIST 54 castrate resistant prostate cancer 54 glioblastoma 54 gastrointestinal stromal tumor 54 sunitinib malate 54 AGILECT R 54 Chronic lymphocytic leukemia 54 relapsed MM 54 erlotinib Tarceva ® 54 hormone refractory 54 efalizumab 54 canakinumab 54 myelofibrosis MF 54 tanespimycin 54 AA Amyloidosis 54 platinum refractory 54 Renal Cell Carcinoma RCC 54 HNSCC 54 voreloxin 54 standard chemotherapy regimens 54 basal cell carcinoma BCC 54 Xanafide 54 docetaxel Taxotere ® 54 fibromyalgia syndrome 54 hematologic malignancies 54 Evoltra ® 54 invasive candidiasis 54 Tavocept 54 anti angiogenic therapy 54 chronic myocardial ischemia 53 non metastatic osteosarcoma 53 SUTENT ® 53 myeloproliferative disorders 53 pemphigus vulgaris 53 immunomodulatory therapy 53 Pancreatic neuroendocrine tumors 53 gemcitabine chemotherapy 53 Inhaled anthrax 53 nasopharyngeal cancer 53 metastatic bladder 53 ZYBRESTAT TM 53 refractory AML 53 bone metastases 53 carcinoid cancer 53 Lupus Nephritis 53 biliary tract cancer 53 leiomyosarcoma 53 ACZ# 53 HGS# 53 lumiliximab 53 Idiopathic pulmonary fibrosis 53 hematological malignancies 53 non squamous NSCLC 53 Angioedema 53 diabetic gastroparesis 53 HER2 positive metastatic breast 53 Idiopathic Pulmonary Fibrosis IPF 53 Inflammatory breast cancer 53 Acute Myelogenous Leukemia 53 lomitapide 53 hematological diseases 53 PANVAC VF 53 relapsing remitting multiple sclerosis 53 sorafenib Nexavar 53 Bezielle 53 imatinib resistance 53 proliferative retinopathy 53 ELACYT 53 metastatic neuroendocrine tumors 53 Cutaneous T 53 NATRECOR R 53 visilizumab 53 Symadex 53 systemic lupus erythematosus 53 NSCLC 53 tigecycline 53 PEGylated interferon beta 1a 53 Voreloxin 53 receptor tyrosine kinase inhibitor 53 samalizumab 53 noninfectious uveitis 53 tyrosine kinase inhibitors 53 oxypurinol 53 skeletal metastases 53 riociguat 53 HIV HCV coinfected 53 Bronchiectasis 53 fallopian tube carcinoma 53 gouty arthritis 53 DVT PE 53 Asentar 53 multiple myeloma 53 metastatic RCC 53 rindopepimut 53 hepatorenal syndrome 53 NOXAFIL 53 CBLC# 53 lung cancer NSCLC 53 cytotoxic chemotherapy 53 glioblastoma multiforme GBM 53 Synovial sarcoma 53 radiochemotherapy 53 TKI therapy 53 neoadjuvant chemotherapy 53 gefitinib Iressa 53 acute myelogenous leukemia 53 PSADT 53 gastrointestinal malignancies 53 CCX# B 53 ZACTIMA 53 progressive multifocal leukoencephalopathy PML 53 cardiac toxicity 53 metastatic disease 53 TORISEL 53 ALCL 53 mRCC 53 grade serous ovarian 53 azacitidine 53 bendamustine 53 Velcade bortezomib 53 HER2 positive cancers 53 alveolar rhabdomyosarcoma 53 TACI Ig 53 Aplidin 53 doxorubicin Adriamycin 53 Phase Ib II 53 decitabine 52 acute ischemic stroke 52 refractory ovarian cancer 52 neoadjuvant therapy 52 glufosfamide 52 bortezomib Velcade R 52 recurrent GBM 52 mycosis fungoides 52 ruboxistaurin 52 prostate cancer PCa 52 Venous thromboembolism 52 palifosfamide 52 BCR ABL inhibitors 52 brain tumor glioblastoma multiforme 52 obatoclax 52 enzastaurin 52 APPRAISE 52 refractory acute myeloid 52 homozygous familial hypercholesterolemia 52 Meningococcal infection 52 systemic fungal infections 52 Surgical resection 52 carcinoid 52 Zolinza 52 epithelial tumors 52 Ph + ALL 52 YONDELIS 52 squamous cell carcinoma SCC 52 K ras mutations 52 pomalidomide 52 docetaxel chemotherapy 52 hematological cancers 52 sorafenib Nexavar ® 52 percutaneous cryoablation 52 dasatinib Sprycel ® 52 inflammatory acne 52 Gorlin syndrome 52 Cloretazine 52 myeloproliferative diseases 52 locoregional 52 xenograft models 52 fungoides 52 relapsed refractory multiple myeloma 52 thalidomide Thalomid 52 Gemzar ® 52 post herpetic neuralgia PHN 52 prostate cancer CaP 52 angiogenesis inhibitor 52 intravenous bisphosphonates 52 metastatic GIST 52 chronic myeloid leukemia CML 52 iclaprim 52 Phenoptin 52 OPAXIO 52 anti angiogenic agents 52 Basal cell 52 nilotinib 52 squamous 52 galiximab 52 BRIM2 52 Severe Sepsis 52 Diabetic Macular Edema 52 lymphocytic leukemia 52 evaluating tivozanib 52 Allovectin 7 52 CHOP chemotherapy 52 EOquin 52 hypereosinophilic syndrome 52 Hodgkin lymphoma HL 52 metastatic gastric 52 atypical Hemolytic Uremic Syndrome 52 Myelodysplastic syndromes MDS 52 papillary renal cell carcinoma 52 adjuvant radiation 52 advanced metastatic renal 52 leukoencephalopathy 52 imatinib resistant 52 pancreatic carcinoma 52 leukemia ALL 52 HER2 positive breast cancer 52 prostate cancer HRPC 52 Acute Coronary Syndromes ACS 52 neratinib 52 anti TNF alpha 52 FOLFOX4 52 gemcitabine Gemzar ® 52 AP# [003] 52 PNP inhibitor 52 demonstrated antitumor activity 52 Phase #b/#a clinical 52 HBeAg negative 52 OMAPRO 52 Phase #/#a trial 52 Amrubicin 52 chemotherapeutic agent 52 vinca alkaloid 52 biologic therapies 52 liver metastases 52 Neulasta ® 52 psoriatic arthritis PsA 52 EVIZON 52 AA amyloidosis 52 HGS ETR1 52 ZYBRESTAT fosbretabulin 52 myelodysplastic syndromes 52 CMV infection 52 cetuximab Erbitux 52 peritoneal carcinomatosis 52 Lennox Gastaut syndrome 52 relapsed ovarian cancer 52 Vandetanib 52 TTR amyloidosis 52 Cloretazine ® 52 dacetuzumab 52 Advaxis Phase 52 evaluating Xcytrin 52 bone metastasis 52 plasminogen activators 52 cutaneous melanoma 52 INCB# [003] 52 Gastric cancer 52 Pulmonary hypertension 52 Ceflatonin R 52 Myelofibrosis 52 Fludarabine 52 chronic plaque psoriasis 52 brivaracetam 52 actinic keratosis 52 metastatic castration resistant 52 EXJADE 52 OvaRex ® MAb 52 myeloid leukemia 52 CTCL 52 carcinoid syndrome 52 EMPOWER ™ 51 pleural mesothelioma 51 tivozanib 51 Vojo Vukovic MD Ph.D. 51 relapsing remitting 51 AEG# 51 pancreatic neuroendocrine tumors 51 alkylating agent 51 upper gastrointestinal bleeding 51 Hodgkin lymphoma NHL 51 NOMID 51 DMARDs 51 virological failure 51 proliferative diabetic retinopathy 51 KRAS mutant tumors 51 Ambrisentan 51 grade cervical intraepithelial 51 refractory colorectal cancer 51 evaluating mipomersen 51 GIST 51 CIMZIA TM certolizumab pegol 51 PROSTVAC VF 51 Panzem R NCD 51 EDEMA3 51 rituximab Rituxan 51 Etanercept 51 metastatic sarcomas 51 terlipressin 51 cilengitide 51 HoFH 51 metastatic renal cell 51 acute PAO 51 secondary hyperparathyroidism 51 diabetic kidney 51 rALLy clinical trial 51 Chronic lymphocytic leukemia CLL 51 Cell Lymphoma 51 bevacizumab Avastin 51 Golimumab 51 Nilotinib 51 doxorubicin docetaxel 51 PROSTVAC ® 51 Gleevec imatinib 51 refractory chronic lymphocytic 51 LymphoStat B 51 bosutinib 51 OvaRex R 51 nonalcoholic steatohepatitis NASH 51 kidney urologic 51 liver metastasis 51 Diffuse Large B 51 VZV 51 Carcinoid tumors 51 tafamidis 51 LHRH antagonists 51 Cloretazine R 51 Pancreatic NET 51 colorectal lung 51 vertebral compression fractures 51 Metastatic melanoma 51 thromboembolic events 51 KRAS status 51 VEGF inhibitors 51 juvenile idiopathic arthritis 51 HCV infection 51 palifermin 51 acetonide FA 51 systemic lupus erythematosus SLE 51 ixabepilone 51 Zemplar Capsules 51 motesanib 51 myelofibrosis polycythemia vera 51 pertuzumab 51 castration resistant prostate cancer 51 unique alkylating agent 51 metastatic colorectal cancer 51 Fibrin Pad 51 refractory metastatic colorectal cancer 51 Telintra 51 Seliciclib 51 resistant ovarian cancer 51 Myelodysplastic Syndrome MDS 51 curable cancers 51 immunosuppressive therapies 51 idarubicin 51 colorectal cancer CRC 51 Arranon 51 de novo AML 51 mycophenolate mofetil 51 chronic myeloid 51 ENGAGE AF TIMI 51 OXi# 51 Esophageal cancer 51 axitinib 51 HSCT 51 HeFH 51 Myelodysplastic Syndrome 51 Targretin capsules 51 elacytarabine 51 metastatic kidney 51 Folotyn 51 stage IIIB 51 histologic subtype 51 pegfilgrastim 51 mapatumumab 51 zalutumumab 51 Alzheimer Disease AD 51 metastatic CRC 51 osteosarcoma rare 51 relapsed MCL 51 VFEND 51 teriflunomide 51 vascular disrupting agent 51 delayed CINV 51 bortezomib Velcade 51 Mucositis 51 Benign prostatic hyperplasia BPH 51 Treanda 51 double blinded placebo 51 refractory gout 51 endometrial hyperplasia 51 Acute myelogenous leukemia 51 TKIs 51 Occlusive Disease 51 Xelox 51 chronic myelogenous leukemia CML 51 NMIBC 51 sunitinib 51 histologies 51 ZACTIMA TM ZD# 51 DFMO 51 IV metastatic melanoma 51 severe sepsis 51 Toxicities 51 Lung transplantation 51 Acute Promyelocytic Leukemia 51 ADVEXIN therapy 51 basal cell cancers 51 HuMax EGFr 51 tocilizumab 51 Targretin 51 Adjuvant chemotherapy 51 cediranib 51 follicular lymphomas 51 acute promyelocytic leukemia 51 IV NSCLC 51 Genasense ® 51 glioblastomas 51 TREANDA 51 acute coronary syndromes 51 homozygous FH 51 nab paclitaxel 51 Acute lymphoblastic leukemia 51 primary immunodeficiency PI 51 ara C 51 Irinotecan 51 relapsed leukemia 51 tumors GIST 51 Erlotinib 51 adalimumab Humira 51 Systemic lupus erythematosus SLE 51 metastatic malignant 51 metastatic uveal melanoma 51 nosocomial pneumonia 51 idiopathic thrombocytopenic purpura ITP 51 tumor recurrence 51 locoregional recurrence 51 antibody MAb 51 ADAGIO study 51 abiraterone acetate 51 vinorelbine 51 OHR/AVR# 51 Neutropenia 51 dose cohorts 51 myelodysplastic syndromes MDS 51 Wegener granulomatosis 51 JAK inhibitor 51 dasatinib Sprycel 51 Safinamide 51 irinotecan chemotherapy 51 resectable 51 erlotinib Tarceva 51 infusional 5-FU/LV 51 Pemetrexed 51 hepatocellular carcinoma HCC 51 chemoradiotherapy 51 phase IIb study 51 metastatic colorectal carcinoma 51 geographic atrophy 51 astrocytoma 51 anticancer therapy 51 recurrent glioma 51 Gliomas 51 thoracic aortic disease 51 concurrent chemoradiation 50 JP-#/fipamezole 50 OncoVEX GM CSF 50 imatinib Gleevec ® 50 phase IIa clinical 50 Tyrosine Kinase Inhibitors 50 BAY #-# 50 metastatic prostate cancer 50 renal cell carcinoma 50 nonalcoholic steatohepatitis 50 hematologic cancers 50 unresectable stage 50 stable angina 50 follicular lymphoma 50 Bortezomib 50 oropharyngeal candidiasis 50 metastatic hormone refractory 50 BRAF inhibitor 50 cutaneous squamous cell carcinoma 50 Torisel 50 Archexin 50 Radiofrequency ablation 50 dasatinib 50 LUMINATE 50 Cabazitaxel 50 phase III ACCLAIM 50 advanced medullary thyroid 50 CTAP# Capsules 50 Azedra 50 Waldenstrom macroglobulinemia 50 thrombotic complications 50 EGFR TKI 50 relapsing multiple sclerosis 50 EOquin TM 50 PFO migraine 50 dacarbazine 50 Malignant pleural mesothelioma 50 EDEMA4 50 eosinophilic pneumonia 50 EGFR mutation positive 50 unresectable tumors 50 Degarelix 50 Radical prostatectomy 50 precancerous cervical lesions 50 NEUVENGE 50 NSABP C 50 Candida infection 50 haematological malignancies 50 Vidaza azacitidine 50 Gastrointestinal Stromal Tumors 50 Prostatitis 50 rNAPc2 50 Anaplastic 50 lumbar spinal stenosis LSS 50 RRMS patients 50 soft tissue sarcomas 50 invasive fungal infection 50 neovascular diseases 50 sargramostim 50 nonmelanoma skin cancers 50 pazopanib 50 chronic HCV 50 mg/m2 dose 50 colorectal carcinoma 50 atherothrombotic events 50 allogeneic stem cell 50 Cloretazine R VNP#M 50 dosage regimens 50 phase IIb trial 50 Hematologic 50 atypical hemolytic uremic syndrome 50 ADVEXIN 50 Romidepsin 50 Triapine 50 indolent follicular non 50 talactoferrin 50 decompensated heart failure 50 TELCYTA 50 acute myeloid leukemia AML 50 INCB# [001] 50 VADT 50 portal vein thrombosis 50 figitumumab 50 refractory Hodgkin lymphoma 50 diabetic nephropathy 50 eculizumab 50 AMN# [001] 50 minimally symptomatic 50 fatal neurodegenerative disorder 50 systemic juvenile idiopathic 50 juvenile idiopathic arthritis JIA 50 relapsed CLL 50 vidofludimus 50 Malignant Melanoma 50 GISTs 50 dermatofibrosarcoma protuberans 50 MGUS 50 Uncontrolled hypertension 50 indolent lymphoma 50 JMML 50 PNH patients 50 anti leukemic 50 dexpramipexole 50 grade glioma 50 imatinib therapy 50 Dengue hemorrhagic fever 50 curative resection 50 UPLYSO 50 dyskeratosis congenita 50 randomized multicenter Phase III 50 imatinib Gleevec 50 PITX2 methylation 50 Cholangiocarcinoma 50 fenretinide 50 elotuzumab 50 sarcomas 50 Myasthenia gravis 50 SPRYCEL ® 50 investigational therapies 50 anthracycline taxane 50 QTc prolongation 50 adverse cytogenetics 50 Troxatyl 50 macrovascular events 50 Chronic Lymphocytic Leukemia CLL 50 metastatic HRPC 50 Doxil ® 50 Progressive Multifocal Leukoencephalopathy 50 Colon polyps 50 fulminant hepatitis 50 interferon beta therapy 50 recurrent VTE 50 acne vulgaris 50 RRMS 50 clinically localized prostate 50 tesetaxel 50 JAK2 inhibitor 50 lenalidomide Revlimid R 50 tumor subtypes 50 potentially hepatotoxic 50 Chronic Myeloid Leukemia 50 HGS ETR2 50 autoantibody positive 50 ADPKD 50 papillary carcinoma 50 eltrombopag 50 Cytoxan 50 BRIM3 50 atherothrombosis 50 Critical limb ischemia 50 CMV disease 50 prostate cancer AIPC 50 Acute Coronary Syndrome 50 hepatocellular carcinoma 50 Temsirolimus 50 cervical lesions 50 tyrosine kinase inhibitors TKIs 50 FOLOTYN 50 hypophosphatasia 50 GnRH agonists 50 tecarfarin 50 myeloproliferative neoplasms 50 PEP# [003] 50 renal anemia 50 Aortic stenosis 50 vismodegib 50 BrachySil TM 50 metastatic colorectal 50 BCR ABL inhibitor 50 taxane chemotherapy 50 ThermoDox R 50 ATTR PN 50 IMC A# 50 panitumumab 50 somatostatin analogues 50 essential thrombocythemia 50 Oral corticosteroids 50 Prostate AdenoCarcinoma Treatment 50 RhuDex ® 50 Epratuzumab 50 hematological disorders 50 IMGN# 50 POAG 50 PegIFN RBV 50 Severe Primary IGFD 50 refractory angina 50 IFN beta 50 angiographic outcomes 50 gastrointestinal stromal tumors 50 epithelial ovarian cancer 50 DAPT 50 pan HDAC inhibitor 50 CRVO 50 Fabry Disease 50 KRAS mutation 50 Malignant glioma 50 Phase #b/#a 50 humanised monoclonal antibody 50 prostate cancer CRPC 50 IMA# 50 Octreolin 50 ankylosing spondylitis AS 50 Stent thrombosis 50 acute coronary syndromes ACS 50 chronic hepatitis C. 50 severe oral mucositis 50 Fx #A 50 malignant pheochromocytoma 50 AFib 50 LymphoStat B belimumab 50 ADVEXIN clinical 50 B CLL 50 neurologic progression 50 Fibrillex TM 50 anaplastic astrocytoma 50 NeuroStar TMS Therapy 50 unresectable 50 systemic mastocytosis 50 inherited neurodegenerative disorder 50 APEX PD 50 premalignant 50 rheumatologic 50 Revlimid lenalidomide 50 interstitial lung disease 50 variceal bleeding 50 urothelial cancer 50 Acute Myeloid Leukemia AML 50 lapatinib Tykerb 50 Acute Myeloid Leukaemia AML 50 advanced carcinoid 50 thyrotoxicosis 50 dose cohort 50 systemic scleroderma 49 recurrent myocardial infarction 49 Malignant mesothelioma 49 hypomethylating agents 49 Aflibercept 49 Myelodysplastic Syndromes 49 docetaxel Taxotere R 49 renal tumors 49 Phase Ib IIa 49 lupus renal disease 49 cranial radiation 49 TOLAMBA 49 CLL 49 Advagraf 49 Medullary thyroid cancer 49 postoperative pulmonary 49 INVEGA ® 49 tumor necrosis 49 infantile spasms 49 Liver transplantation 49 Recurrences 49 lymphomas 49 leukemia CLL 49 DCVax ® Brain 49 peritoneal cancer 49 oral methylnaltrexone 49 refractory CLL 49 distant metastasis 49 diastolic heart 49 diffuse intrinsic pontine glioma 49 Bloodstream infections 49 Cell Lymphoma CTCL 49 HCV SPRINT 49 diagnosed multiple myeloma 49 solid tumors 49 aHUS 49 follicular lymphoma FL 49 metastatic adenocarcinoma 49 Evoltra 49 Genz # 49 T#I mutant 49 Dasatinib 49 squamous cell lung cancer 49 vWD 49 pouchitis 49 nonsmall cell lung cancer 49 ALA PDT 49 Idiopathic Thrombocytopenic Purpura ITP 49 Ulcerative colitis 49 relapsed refractory 49 chemotherapy regimens 49 paraganglioma 49 Thrombocytopenia 49 cardio renal 49 Sorafenib 49 Herceptin trastuzumab 49 Severe hypersensitivity reactions 49 familial adenomatous polyposis 49 tamibarotene 49 squalamine 49 invasive lobular carcinoma 49 bevacizumab Avastin ® 49 adalimumab 49 recurrent prostate cancer 49 octreotide 49 NYHA Class II 49 cervical dysplasia 49 paroxysmal atrial fibrillation 49 gastric adenocarcinoma 49 coinfected patients 49 olaparib 49 nonmelanoma skin cancer 49 disease progression 49 Osteosarcoma 49 Natalizumab 49 metastatic HER2 negative 49 Pancreatic cancer 49 CLORETAZINE TM VNP#M 49 TELINTRA 49 hepatitis C genotype 49 CIPN 49 curative therapy 49 Heavy menstrual bleeding 49 Stedivaze 49 PRECISE trial 49 sorafenib 49 FOLFOX chemotherapy 49 PCNSL 49 eosinophilic asthma 49 Allovectin 7 ® 49 varicella infection 49 SCCHN 49 Testicular cancer 49 adjuvant therapy 49 purpura 49 MGd 49 CIMZIA ™ 49 indolent lymphomas 49 cMET 49 Taxotere ® 49 malignancies 49 DLBCL 49 trastuzumab Herceptin ® 49 PRESEPT study 49 chronic GVHD 49 atrasentan 49 acute myocardial infarction AMI 49 Fludara 49 neoadjuvant treatment 49 Li Fraumeni Syndrome 49 anti TNF 49 Malignant Glioma 49 distant metastases 49 acute lymphoblastic 49 pediatric pontine glioma 49 Atypical Hemolytic Uremic Syndrome 49 Hurthle cell 49 Chronic pancreatitis 49 medically inoperable 49 cholangiocarcinoma 49 advanced NSCLC 49 relapsed Hodgkin lymphoma 49 hormone refractory prostate cancer 49 paclitaxel Taxol ® 49 diagnosed glioblastoma multiforme 49 intravesical therapy 49 Folfox 49 dosing cohorts 49 essential thrombocythemia ET 49 vorinostat 49 Soft Tissue Sarcoma 49 Perifosine 49 Pixantrone 49 factor TNF 49 Phase IIb clinical trials 49 INCB# [002] 49 hematologic disorders 49 temsirolimus 49 bortezomib 49 MIST II 49 bucindolol 49 lorvotuzumab mertansine 49 Meningiomas 49 refractory indolent non 49 relapsing MS 49 thymic carcinoma 49 zanolimumab 49 heavily pretreated patients 49 CIDP 49 antiangiogenic therapy 49 OVATURE 49 serous ovarian cancer 49 DXL# 49 EGFR inhibitors 49 CYT# 49 QVA# 49 non squamous 49 Dalbavancin 49 PAOD 49 Vitamin B# deficiency 49 Nephrogenic Systemic Fibrosis NSF 49 MabCampath 49 acute GvHD 49 huN# DM1 49 neoadjuvant 49 Cinquil 49 oral leukoplakia 49 paclitaxel eluting stents 49 cytoreduction 49 Glybera R 49 coronary revascularization 49 post thrombotic syndrome 49 fluoropyrimidine 49 ARCOXIA 49 Acute Myeloid Leukemia 49 Cotara 49 GIST tumors 49 estramustine 49 Enzastaurin 49 chemoradiation 49 thyroid nodules 49 XIENCE V demonstrated 49 standard chemotherapy regimen 49 alemtuzumab Campath 49 Virulizin ® 49 myeloproliferative disease 49 antiangiogenic agents 49 SUTENT 49 TRISENOX 49 chemo radiotherapy 49 adjuvant tamoxifen 49 lymphoma leukemia 49 Atiprimod 49 CTEPH 49 superficial basal cell carcinoma 49 solar keratoses 49 leiomyomas 49 capecitabine Xeloda R 49 panobinostat 49 perioperatively 49 biologic therapy 49 hyperphosphatemia 49 FOLPI 49 ANCA associated 49 commercialize deforolimus 49 relapsed GBM 49 histone deacetylase HDAC inhibitor